MediciNova, Inc.
MNOV
Rank in Stocks
#21169
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and... MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Share Price
$1.47
Last synced: 2026-11-09
Market Cap
$72.36M
Change (1 day)
0.68%
Change (1 year)
-8.70%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MediciNova, Inc. (MNOV)
Category
Healthcare
Operating Margin for MediciNova, Inc. (MNOV)
Operating Margin as of November 2026 TTM: -1,287.41%
According to MediciNova, Inc.'s latest financial reports, its current operating margin (TTM) is -1,287.41%. At the end of 2025 the company had an operating margin of -3,242.47%.
Operating Margin history for MediciNova, Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,287.41% | -60.30% |
| 2025 | -3,242.47% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -990.03% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -253.02% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -66.97% | -95.09% |
| 2012 | -1,363.77% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | -20.27% | -99.87% |
| 2006 | -15,794.30% | 322.09% |
| 2005 | -3,741.93% | -62.26% |
| 2004 | -9,915.19% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.88% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MediciNova, Inc.'s operating margin
What is MediciNova, Inc.'s operating margin?
MediciNova, Inc.'s operating margin is -1,287.41%, as of Nov 2026.
What was MediciNova, Inc.'s operating margin in 2025?
In 2025, MediciNova, Inc.'s operating margin was -3,242.47%, compared with 0.00% in 2024.
How has MediciNova, Inc.'s operating margin changed since 2020?
From 2020 to 2025, MediciNova, Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-3,242.47%).
How does MediciNova, Inc.'s operating margin compare with similar companies?
MediciNova, Inc.'s operating margin (-1,287.41%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.